EFB Dengue Literature Review

CXCR5

4 min read

CXCR5

Overview

CXCR5 is a chemokine receptor for CXCL13, the follicle-associated chemokine. CXCR5 expression enables B cells to home to B cell follicles in secondary lymphoid organs. Its presence or absence on IgD⁻CD27⁻ (DN) B cells is the primary criterion for discriminating DN1 (CXCR5⁺, follicle-homing) from DN2 (CXCR5⁻, extrafollicular) subsets.

Key Points from Literature

  • DN1/DN2 discrimination: CXCR5 vs. CD19 on pre-gated IgD⁻CD27⁻ cells separates DN1 (CXCR5⁺, CD19 intermediate) from DN2 (CXCR5⁻, CD19^hi). In healthy donors, DN1 (CXCR5⁺) is the majority; in active SLE, DN2 (CXCR5⁻) dominates (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • CXCR5 absence as extrafollicular marker: Loss of CXCR5 on DN2 cells is consistent with exclusion from B cell follicles — a hallmark of extrafollicular effector B cells. aNAV cells also lack CXCR5 (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • Transcriptional validation: CXCR5 is among the genes uniquely low in DN2 cells by RNA-seq, with ZEB1 binding motifs enriched in genes with low DN2 expression including CXCR5 (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • NAV and SWM subsets also stratified by CXCR5: Within NAV cells, rNAV are CXCR5⁺ while aNAV are CXCR5⁻. Within SWM, the majority are CXCR5⁺. CXCR5 loss thus marks the extrafollicular activation state across multiple B cell subsets (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • CXCR5 can substitute for CD21 in gating: CXCR5 vs. CD11c staining identifies the same B cell subsets as CD21 vs. CD11c (DN1/DN2 in DN gate; resting vs. activated in naive and memory gates). This substitutability provides practical flexibility for panel design when CD21 reagents are unavailable (see Sanz2025 - Human Atypical B Cells Overview, review, Figure 2B–C).

  • CXCR5 decreased in EF populations during acute COVID-19: In CoV-A patients, CXCR5 surface expression was reduced on EF populations (aN, DN2) relative to follicular populations (rN, DN1). Concurrently, CXCR3 (IFN-γ-driven tissue homing receptor) was increased on the same populations. This reciprocal CXCR5↓/CXCR3↑ switch is the most direct in vivo evidence in human infection that EF pathway B cells are programmed for inflammatory tissue homing rather than follicular entry (see Woodruff2020 - EF B Cell Responses in COVID-19, spectral FCM, n=9 CoV-A patients).

  • CXCR5 included in 24-marker spectral B cell panel: CXCR5 was part of the homing marker module (alongside CXCR3, CXCR4, CD62L) in the standardised Woodruff2020 panel design (see Woodruff2020 - EF B Cell Responses in COVID-19, Table 1 / Supplementary Table 1).

  • CXCR5 absence defines Tph cells in dengue: The dominant activated CD4⁺ T cell subset in acute dengue is CXCR5⁻PD-1⁺ (Peripheral Helper T Cell), not CXCR5⁺PD-1⁺ (cTfh). ~75% of activated CD4⁺ T cells lack CXCR5. CXCR5 absence on both Tph (T cells) and DN2 (B cells) positions CXCR5 loss as the unifying marker of EF pathway commitment across both lymphocyte lineages (see Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue, n=170 acute dengue).

  • Concurrent CXCL13 elevation despite Tph dominance: Despite the overwhelming dominance of CXCR5⁻ Tph cells, plasma CXCL13 (the CXCR5 ligand and GC biomarker) is elevated in acute dengue. This suggests concurrent GC activity alongside the dominant EF response — EF and GC may not be mutually exclusive in dengue (see Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue).

Contradictions & Debates

None documented in current wiki sources.

DN2 B Cell, DN3 B Cell, Double-Negative B Cell, Activated Naive B Cell, CD11c, CD21, CXCR3, Extrafollicular Response, Germinal Center, Peripheral Helper T Cell, PD-1

Sources

Graph View

Backlinks